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DeacetylationHuman T-cell leukemia virus type 1 (HTLV-1) infection is associated with the development of adult T-cell
leukemia (ATL) and various inﬂammatory diseases. CD69 is a marker of early activation of lymphocytes.
We investigated the effects of HTLV-1 infection on the expression of CD69. The CD69 gene was upregulated
in all viral protein Tax-expressing HTLV-1-transformed T-cell lines, except MT-2 and peripheral blood mono-
nuclear cells from patients with ATL compared with uninfected T-cell line, Tax-negative ATL-derived T-cell
lines and normal peripheral blood mononuclear cells. Flow cytometric analysis and immunohistochemical
analysis conﬁrmed the enhanced expression of CD69 in HTLV-1-transformed T-cell lines and in ATL cells in
lymph nodes and skin lesions, and its absence in MT-2 and peripheral blood mononuclear cells. CD69 expres-
sion was induced following infection of human T-cell line with HTLV-1, and speciﬁcally by Tax. Tax transcrip-
tionally activated CD69 gene through both nuclear factor-κB and cyclic adenosine 3′,5′-monophosphate
response element-binding protein signaling pathways. Detailed analysis of the CD69 promoter indicated
that the Tax-induced expression of CD69 was regulated by multiple cis-acting elements and by the interplay
of transcription factors of the nuclear factor-κB, early growth response and cyclic adenosine 3′,5′-monophosphate
response element-binding protein families. The lack of CD69 expression in MT-2 is due to epigenetic mechanism
involving deacetylation, but not methylation. We conclude that CD69 is a Tax-regulated gene, and its regulation
by Tax may play a role in cellular activation and HTLV-1-induced disease pathogenesis.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Human T-cell leukemia virus type 1 (HTLV-1) is the causative retro-
virus of adult T-cell leukemia (ATL) [1,2]. It also causes a neurological
disorder known as HTLV-1-associated myelopathy/tropical spastic
paraparesis [3,4], as well as other inﬂammatory diseases such as uveitis
and arthritis [5,6].
CD69 is a type II transmembrane protein of the C-type lectin family
and its gene is located within the natural killer gene complex [7,8]. It iscytidine; CREB, cyclic adenosine
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l rights reserved.a disulﬁde-linked homodimer [8]. In healthy subjects, CD69 is not
detected in peripheral blood lymphocytes, but is expressed on small sub-
sets of T and B cells in peripheral lymphoid tissues [9]. In vitro, the expres-
sion of CD69 is induced early onmost leukocytes upon activation [10]. In
addition, CD69 is selectively expressed on chronic inﬂammatory inﬁl-
trates at the sites of active immune responses in vivo [11,12]. Despite
early data suggesting a proinﬂammatory function for CD69 [10,13], re-
cent data, using different inﬂammatory models, point to an immunoreg-
ulatory role by regulating effector T-cell responses [14–17]. Thus, in the
absence of CD69,mice show an enhanced antitumor activity and develop
exacerbated forms of arthritis, myocarditis, asthma and skin contact
hypersensitivity [14–17]. The ﬁnding that CD69 acts as an inhibitor of
tumor immunosurveillance [14] raises the possibility that its expression
onHTLV-1-infected T cells could inﬂuence the antiviral immune response
and underlie the immunosuppression seen in HTLV-1-associated dis-
eases. Other roles for CD69 have been reported in previous studies,
e.g., regulation of cell migration [18–20].
The pX region of the HTLV-1 genome encodes several regulatory
and accessory viral proteins, including the transactivating protein
Tax, which is essential for viral gene expression and replication
[21–24]. Tax modulates the expression of cellular genes that impact
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aim of the present study was to determine the effect of HTLV-1 and
Tax on the expression of CD69 gene in T lymphocytes.
2. Materials and methods
2.1. Cell culture
The HTLV-1-transformed T-cell lines MT-2 [25], MT-4 [26], C5/MJ
[27] and HUT-102 [2], ATL-derived T-cell lines, MT-1 [28], TL-OmI [29]
and ED-40515(−) [30], and the HTLV-1-negative human T-cell lympho-
cytic cell line Jurkat were cultured in RPMI 1640medium supplemented
with 10% fetal bovine serum and antibiotics. TY8-3/MT-2 was esta-
blished from the interleukin-2 (IL-2)-dependent human T-cell line
TY8-3, coculturedwithmitomycin C-treatedMT-2 cells, andwas capable
of growth completely independent of IL-2 [31]. In JPX-9 cells, Tax is
under the transcriptional control of the metallothionein gene promoter
and can be induced by the addition of CdCl2 to the medium [32]. Exper-
iments using JPX-9 cells were carried out after a 3-day cultivation period
in the absence and presence of 20 μM of CdCl2. Peripheral blood mono-
nuclear cells (PBMCs) were isolated from 2 healthy volunteers, 14 pa-
tients with acute type ATL and 2 patients with chronic type ATL, using
Ficoll-Paque density gradient centrifugation (GE Healthcare Biosciences,
Uppsala, Sweden). To use activated T cells, PBMCs were stimulated with
10 μg/ml phytohemagglutinin (PHA) for 72 h. Some cell cultures were
supplemented with 5-azacytidine (5-Aza; Sigma-Aldrich, St. Louis, MO,
USA), a known inhibitor of DNAmethylation, or suberoylanilide hydrox-
amic acid (SAHA; Alexis, Lausen, Switzerland), a known inhibitor of his-
tone deacetylases. All samples were collected at the time of admission to
the hospital before the commencement of chemotherapy. The diagnosis
of ATL was based on clinical features, hematological ﬁndings and the
presence of anti-HTLV-1 antibodies in the serum. Informed consent
was obtained from all blood donors.
2.2. RNA detection
Total RNA was prepared from various cell cultures by Trizol
(Invitrogen, Carlsbad, CA, USA) according to the protocol provided by
the manufacturer. First-strand cDNA was synthesized from 1 μg total
cellular RNA using a PrimeScript RT-PCR kit (Takara Bio Inc., Otsu,
Japan) with random primers. The primers used were 5′-CATAGCTC
TCATTGCCTTATCAGT-3′ (forward) and 5′-CCTCTCTACCTGCGTATCGT
TT-3′ (reverse) for CD69, 5′-CCGGCGCTGCTCTCATCCCGGT-3′ (forward)
and 5′-GGCCGAACATAGTCCCCCAGAG-3′ (reverse) for Tax in HTLV-1-
infected T-cell lines and ATL cells, 5′-ATCGGCTCAGCTCTACAGTTCCT-3′
(forward) and 5′-ATTCGCTTGTAGGGAACATTGGT-3′ (reverse) for Tax
in JPX-9 and Jurkat cells transfected with Tax, 5′-ATCCCACACGCCA
CATTCAAAGC-3′ (forward) and 5′-TGCCCCACCACGAAATGATAAAT-3′
(reverse) for IL-2 receptor α chain (IL-2Rα), 5′-ATTGCTCTCACTTGCC
TTGGCG-3′ (forward) and 5′-CATGCAAGCTGGAAAACTGCCC-3′
(reverse) for IL-13, 5′-GCCAAGGTCATCCATGACAACTTTGG-3′ (for-
ward) and 5′-GCCTGCTTCACCACCTTCTTGATGTC-3′ (reverse) for
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and 5′-GTG
GGGCGCCCCAGGCACCA-3′ (forward) and 5′-CTCCTTAATGTCACGC
ACGATTTC-3′ (reverse) for β-actin. The length of the semiquantita-
tive reverse transcription-PCR (RT-PCR) for each gene was as fol-
lows; 25, 30 or 35 cycles for CD69, 25, 30 or 35 cycles for Tax,
25 cycles for IL-2Rα, 35 cycles for IL-13, 27 cycles for GAPDH and
28 cycles for β-actin. The PCR products were fractionated on 2%
agarose gels and visualized by ethidium bromide staining.
2.3. Transfection and luciferase assay
Luciferase assays were performed to conﬁrm that Tax induces the
CD69 promoter. Transient transfections were carried out in 5 × 106
Jurkat cells with 5 μg of the luciferase reporter plasmid, togetherwith 1–5 μg of the effector plasmid (Taxwild type or its mutant expres-
sion vectors) by electroporation (250 V, 960 μF). For Tax expression,
the plasmid vector pβMT-2 Tax (forwild type Tax) and the Taxmutants
M22 and Tax-703 were used [33]. The CD69 promoter-luciferase gene
constructs have already been described [34,35]. The single and com-
bined internal deletion mutants of nuclear factor-κB (NF-κB) sites
were constructed by deletion of the NF-κB sites of the plasmid pAIM
255-luc. The IκBαΔN- and IκBβΔN-dominant-negative mutants are
IκBα and IκBβ deletion mutants lacking the N-terminal 36 and 23
amino acids, respectively [36,37]. The dominant-negative mutants of
IκB kinase (IKK)α, IKKα (K44M), IKKβ, IKKβ (K44A), IKKγ, IKKγ
(1–305) and NF-κB-inducing kinase (NIK), NIK (KK429/430AA) have
been described previously [38,39]. The dominant-negative mutants of
cyclic adenosine 3′,5′-monophosphate response element-binding pro-
tein (CREB), pCMV-KCREB and pCMV-CREB133, were purchased from
Clontech Laboratories (Mountain View, CA, USA). In all cases, the refer-
ence plasmid phRL-TK, which contains the Renilla luciferase gene
under the control of the herpes simplex virus thymidine kinase promot-
er, was cotransfected to correct for transfection efﬁciency. After 24 h,
transfected cells were collected by centrifugation, washed with
phosphate-buffered saline, and lysed in reporter lysis buffer (Promega,
Madison, WI, USA). Luciferase assays were conducted using the dual lu-
ciferase reporter system (Promega), in which the relative luciferase ac-
tivity was calculated by normalizing transfection efﬁciency according
to the Renilla luciferase activities.
2.4. Immunoblots
Cellswere lysed in a buffer containing 62.5 mMTris–HCl (pH 6.8), 2%
sodium dodecyl sulfate, 10% glycerol, 6% 2-mercaptoethanol and 0.01%
bromophenol blue. The protein concentration was determined by the
Bradford assay (Bio-Rad, Hercules, CA, USA). Samples (20 μg) were
subjected to electrophoresis on sodium dodecyl sulfate-polyacrylamide
gels followed by transfer to a polyvinylidene diﬂuoride membrane and
probing with the speciﬁc antibodies. The mouse anti-actin monoclonal
antibody was purchased from NeoMarkers (Fremont, CA, USA). Mouse
monoclonal antibody to Tax, Lt-4, was described previously [40]. The im-
munoblots were then developed by using the enhanced chemilumines-
cence system (Amersham Biosciences, Piscataway, NJ, USA).
2.5. Flow cytometry
Expression of CD69 was analyzed by ﬂow cytometry with phycoer-
ythrin (PE)-labeled mouse monoclonal antibody against CD69 (clone
TP1.55.3; Beckman Coulter, Fullerton, CA, USA). Analyses were carried
out with isotype-matched control antibody. The cells were incubated
with the antibody for 30 min, washed with cell WASH (Becton Dickin-
son Immunocytometry Systems, San Jose, CA, USA), and thenmeasured
in the cytometer.
2.6. Preparation of nuclear extracts and electrophoretic mobility shift assay
(EMSA)
Nuclear proteins were extracted and transcription factors bound to
speciﬁc DNA sequenceswere examined by EMSA, as described previous-
ly [41]. The top strand sequences of the oligonucleotide probes or com-
petitors were as follows: for the NF-κB element (κB1) of the CD69
gene, 5′-GATCCAGACAACAGGGAAAACCCATACTTC-3′; for the NF-κB ele-
ment (κB2) of the CD69 gene, 5′-GATCCAGAGTCTGGGAAAATCCCAC
TTTCC-3′; for the NF-κB element of the IL-2Rα gene, 5′-GATCCG
GCAGGGGAATCTCCCTCTC-3′; and for the AP-1 element of the IL-8 gene,
5′-GATCGTGATGACTCAGGTT-3′. The oligonucleotide 5′-GATCTGTCGAA
TGCAAATCACTAGAA-3′, containing the consensus sequence of the
octamer binding motif, was also used to identify speciﬁc binding of the
transcription factor Oct-1, which regulates the transcription of a number
of so-called housekeeping genes. The above underlined sequences are
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proteins in the DNA-protein complex shown by EMSA, we used antibod-
ies speciﬁc for various NF-κB family proteins, including p50, p65, c-Rel,
p52 and RelB (Santa Cruz Biotechnology, Santa Cruz, CA, USA). These an-
tibodies were incubated with the nuclear extracts for 45 min at room
temperature before incubation with radiolabeled probes.
2.7. Immunohistochemical analysis
Biopsy samples were taken from the lesional skin of 5 patients with
ATL and lymph nodes of 6 patients with ATL. CD69 immunohistochemis-
try was performed using a mouse anti-CD69 monoclonal antibody
(BioLegend, San Diego, CA, USA) after pretreatment of the deparaﬁnized
tissue sections with ready-to-use proteinase K (Dako, Carpinteria, CA,
USA). The sections were counterstained with methyl green, hydrated
in ethanol, cleaned in xylene, andmounted. The stained cellswere exam-
ined under a light microscope (Axicoskop 2plus; Zeiss, Jena, Germany)
with an Achroplan × 40/0.65 lens (Zeiss). Images were acquired with
an AxioCam MRC camera and AxioVision 4.7 software (Zeiss). Informed
consent was obtained from all tissue donors.
3. Results
3.1. Upregulated CD69 expression in Tax-expressing HTLV-1-transformed
T-cell lines
We investigated ﬁrst whether the CD69mRNA upregulation is a gen-
eral feature of HTLV-1-infected T cells. RNA from several T-cell lines was
isolated and analyzed by RT-PCR (Fig. 1A). HTLV-1-transformed T-cell
lines, including MT-2, MT-4, C5/MJ and HUT-102, constitutivelyFig. 1. Expression of CD69 in HTLV-1-infected T-cell lines. (A) RT-PCR analysis of CD69, Tax a
line (lane 8), MT-2, MT-4, C5/MJ and HUT-102 HTLV-1-transformed T-cell lines (lanes 1–4
cytometry of the indicated human T-cell lines. Cells were either stained with anti-CD69-PE
ﬂow cytometry. The relative number of cells (ordinate) is plotted against the relative ﬂuorexpressed Tax at mRNA and protein levels. Furthermore, these T-cell
lines, excluding MT-2, contained CD69 transcripts. In contrast, MT-1,
TL-OmI and ED-40515(−), which are T-cell lines of leukemic cell origin
that had been established from patients with ATL, did not express Tax
protein. All ATL-derived T-cell lines, MT-1, TL-OmI and ED-40515(−),
and the uninfected T-cell line, Jurkat, did not contain detectable amounts
of CD69 transcripts.
To analyze whether increased mRNA synthesis results in increased
expression on the cell surfaces, direct immunoﬂuorescence staining
and ﬂow cytometrywere performed. The experiments showed high ex-
pression of CD69 on the cell surface of HTLV-1-transformed T-cell lines,
includingMT-4, C5/MJ and HUT-102 (Fig. 1B). In contrast, MT-2 and the
ATL-derived MT-1, TL-OmI and ED-40515(−), and uninfected Jurkat
cell lines hardly expressed CD69 on the cell surface (Fig. 1B). These re-
sults indicate that Tax but not HTLV-1 infection induces the expression
of CD69 on T cells.
3.2. Expression of CD69 in leukemic cells from ATL patients
We next examined CD69 expression in patients with ATL. PBMCs
were isolated from patients with ATL and uninfected healthy donors.
We examined CD69 mRNA expression in primary peripheral blood
ATL cells and normal PBMCs under resting and activated conditions
(Fig. 2A). Primary peripheral blood ATL cells from all 11 patients
expressed CD69 at levels higher than normal PBMCs. PHA induced
CD69 mRNA expression in a normal healthy donor. The intensity of
the RT-PCR product of CD69 did not correlate with the level of expres-
sion of Tax in ATL. We also analyzed CD69 expression in PBMCs by
ﬂow cytometry. In normal subjects, CD69was hardly expressed on rest-
ing cells, but was induced after treatment with PHA. In 4 ATL patientsnd GAPDH expression andWestern blot analysis of Tax and actin in Jurkat control T-cell
), and MT-1, TL-OmI and ED-40515(−) ATL-derived T-cell lines (lanes 5–7). (B) Flow
antibody (black/solid) or isotype control-PE antibody (lined/open), and subjected to
escence intensity (abscissa).
Fig. 2. Expression of CD69 in primary ATL cells. (A) RT-PCR analysis of CD69 (top panel), Tax (middle panel) and GAPDH (bottom panel) expression in PBMCs frompatients with ATL and
normal controls. PBMCs from normal control were treated with PHA for 72 h and subjected to RT-PCR (PHA-PBMCs). (B) Flow cytometric analysis of CD69 cell surface expression on
PBMCs obtained from patients with ATL and normal controls, and PHA-PBMCs. Cells were stained with PE-conjugated anti-CD69 antibody (black/solid). A, acute type ATL; C, chronic
type ATL. (C) Immunohistochemical staining of CD69 in ATL lymph nodes and skin lesions. Tissue sections from ATL lymph nodes (n = 6) and skin lesions (n = 5) were stained with
anti-CD69 antibody. Tissue sections were counterstained with methyl green. Representative results from a single donor. Original magniﬁcation, ×400 and ×1200.
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CD69 at high level (Fig. 2B).
We also determined in situ CD69 expression by immunohistochem-
ical staining of CD69 in ATL cells invading lymph nodes (n = 6) and
skin tissues (n = 5). Representative results are shown in Fig. 2C. ATL
cells were positive for CD69 in the membrane of all the tissue samples
examined.
3.3. Tax upregulates CD69 mRNA and protein expression
To substantiate HTLV-1 control of CD69 expression, studies were
performed using the parental TY8-3 cell line and TY8-3 cells infected
with HTLV-1 (TY8-3/MT-2). TY8-3/MT-2 cells demonstrated strong ex-
pression of TaxmRNA [42]. Flow cytometric analysis also demonstrated
upregulation of CD69 protein on the cell surface of TY8-3/MT-2 cells. As
expected, HTLV-1 infection induced CD69 expression (Fig. 3A).
To establish the role of Tax in CD69 upregulation in HTLV-1-
transformed T cells, conditionally Tax-expressing JPX-9 cells were used
(Fig. 3B). This cell line is a Tax-inducible Jurkat subline known to stably
express Tax under the control of a metallothionein promoter [32]. Tax
synthesis was induced by culturing JPX-9 cells in the presence of CdCl2.
Different from untreated JPX-9 cells, CD69 transcripts and expression
of CD69 on the surfaces were increased in JPX-9 cells cultured with
CdCl2 (Fig. 3B and C). As expected, the mRNA expression of IL-2Rα, oneof the known target genes of Tax [43], was also enhanced in JPX-9 cells
(Fig. 3B). Thus, the increased CD69 levels consistently correlated with
Tax expression, conﬁrming the Tax-mediated transactivation of CD69
gene.
As shown in Fig. 2B, peripheral blood ATL cells of only a few patients
expressed CD69 protein. We also examined the coexpression of CD69
and Tax in ATL cells cultured ex vivo. PBMCs were isolated from an ATL
patient (acute type) and cultured without mitogen for 72 h. Although
circulating ATL cells freshly isolated from a patient hardly expressed
TaxmRNA, the expression level increasedmarkedly after 24–72 h of cul-
ture. CpGmethylation of the HTLV-1 long terminal repeat plays a critical
role in repression of viral gene expression in latently infected cells [44].
This increased Tax mRNA expression might be due to reactivation of
viral gene expression. CD69 mRNA and protein were also increased in
primary ATL cells after 72 h of culture, in parallel with Tax mRNA
(Fig. 3D and E). Thus, Tax expression seems to induce CD69 expression
in ATL patients, though such induction could be triggered by yet un-
known factor present in ATL cell culture medium. Taken together,
these results further support the view that Tax induces CD69.
3.4. Tax activates CD69 promoter via NF-κB
Since Tax is a potent transactivating protein [21–24], it is likely
that it induces CD69 expression at transcriptional level. To determine
Fig. 3. HTLV-1 infection and Tax expression induce CD69 expression. (A) Comparison of TY8-3 cells and a virally-transformed cell line. Flow cytometry of TY8-3 and TY8-3/MT-2
cells. Cells were stained with PE-conjugated anti-CD69 antibody. (B) HTLV-1 Tax induced CD69 expression. JPX-9 cells were treated with CdCl2 (20 μM) for 72 h. Total RNA was
isolated from cells, and RT-PCR was carried out for CD69, IL-2Rα, Tax and β-actin (loading control). Western blot analysis was also performed for Tax and actin (loading control).
(C) Flow cytometric analysis of Tax-mediated cell surface expression of CD69. JPX-9 cells were treated with CdCl2 (20 μM) for the indicated time periods. Control cells were
cultured without CdCl2. Cells were stained with direct immunoﬂuorescence for CD69, and subjected to ﬂow cytometric analysis. (D) PBMCs obtained from a patient with
ATL were incubated for the indicated time periods. Total RNA was isolated from cells, and RT-PCR was performed for CD69, Tax and β-actin (loading control). (E) Flow
cytometric analysis of CD69 cell surface expression in PBMCs obtained from a patient with ATL. Cells were cultured for 72 h, and stained with PE-conjugated anti-CD69 anti-
body. A, acute type ATL.
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transfected with a luciferase plasmid containing 1.4-kb fragment of
the CD69 5′-ﬂanking region and Tax expression vectors. Tax signiﬁcant-
ly stimulated luciferase activity in transfected Jurkat cells (Fig. 4A). To
narrow down the signaling pathways relevant to transactivation, Tax
mutants M22 and Tax-703 [33] were cotransfected along with the
CD69 promoter construct. RT-PCR analysis conﬁrmed the expression
of wild type and mutant Tax mRNA (Fig. 4A, bottom panels). As
shown in Fig. 4A, a slight increase of activity was observed with mutant
M22, which is known to activate the CREB transcriptional pathway [33],
but does not stimulate NF-κB transcription factor due to a defect in as-
sociation with IKKγ [45]. Similarly, Tax mutant Tax-703 increased the
promoter activity. This mutant can activate NF-κB [33], but not the
CREB pathway because it does not interact with the p300/CREB binding
protein-associated factor [46]. The combination of both mutants, M22
and Tax-703, resulted in transactivation of the promoter, which even
extended the activity of wild type Tax (Fig. 4A). These results indicate
that at least two Tax functions cooperate to stimulate the CD69
promoter.
To understand the mechanism of transactivation, CD69 promoter
mutants were used. Transfection of these mutants in the presence and
absence of Tax, and subsequent luciferase assays demonstrated that
the progressive removal of 5′-sequences up to position −255 did not
signiﬁcantly inhibit the induced promoter activity, suggesting that the
271-bp fragment, spanning positions −255 to +16, contained theTax-responsive elements (Fig. 4B). Further deletion of upstream se-
quences up to position−170 resulted in partial loss of responsiveness
to Tax. Additional removal of the 5′-sequences up to position−78 fur-
ther affected the inducible promoter activity. The basal promoter activ-
ities in all deleted reporter constructs were almost same.
Two potential NF-κB binding sequences were identiﬁed at positions
−160 (κB1) and −223 (κB2). κB1 and κB2 were identical to those
found in the gene promoters of c-myc and IL-6, respectively [47]. To
test the relative contribution of the NF-κB binding sites to the
Tax-mediated activation of CD69, plasmids with internal deletion mu-
tants of these sites in the CD69 promoter were transfected (Fig. 4C). Sin-
gle deletion of the κB1 and κB2 sites resulted in reduction of the
inducible activity. The combination of double deletions further reduced
Tax-mediated activation of this reporter construct. On the other hand,
three deleted reporter constructs did not have the abilities to suppress
the basal promoter activity of CD69. These results indicate that the two
NF-κB binding sites in the CD69 promoter regulate Tax-induced
upregulation of CD69.
We next examined whether Tax-mediated transactivation of CD69
gene expression involves signal transduction components in NF-κB
activation. For this purpose, we tested the ability of the dominant-
interfering mutants of IκBα, IκBβ and IKKγ, and kinase-deﬁcient
mutants of IKKα, IKKβ and NIK to inhibit Tax-mediated transactivation
of CD69-driven reporter gene activity. The expression of these inhibito-
ry mutants did not affect the basal promoter activity (data not shown),
Fig. 4. HTLV-1 Tax activates CD69 promoter via NF-κB. (A) Jurkat cells were transfected with pAIM 1.4-luc (5 μg) together with pβMT-2 Tax (Tax WT), Tax-M22, Tax-703 or empty
vector alone (1 μg) or the combination of Tax-M22 and Tax-703 using electroporation. Cells were harvested 24 h post-transfection. The expression of wild type Tax and the respec-
tive mutants was analyzed by RT-PCR (bottom panels) and luciferase activity was measured with a luminometer (top panel). The results are represented as fold induction by Tax or
Tax mutants relative to the vector alone. RNA prepared from MT-4 cells was used as a positive control for Tax mRNA. (B) Jurkat cells were transfected with the indicated CD69
luciferase reporter constructs (5 μg) and either empty vector or pβMT-2 Tax (5 μg). The deleted plasmids are indicated on the left side of the ﬁgure. The activities are expressed
relative to that of cells transfected with pXP2 and an empty vector, which was deﬁned as 1. (C) Jurkat cells were transfected with pAIM 255-luc, pAIM 255-luc with deleted distal
NF-κB site [pAIM 255 (κB2−)-luc], pAIM 255-luc with deleted proximal NF-κB site [pAIM 255 (κB1−)-luc] or pAIM 255-luc with double deleted [pAIM 255 (κB2/κB1−)-luc] (5 μg)
together with either empty vector or pβMT-2 Tax (2 μg). Schematic diagrams of the CD69 reporter constructs containing the wild type (pAIM 255-luc) and internal deletion mu-
tants of κB1 and/or κB2 motifs are indicated on the left side of the ﬁgure. The activities are expressed relative to that of cells transfected with pAIM 255-luc and an empty vector,
which was deﬁned as 1. (D) Functional effects of IκBα-, IκBβ- and IKKγ-dominant-interfering mutants and kinase-deﬁcient IKKα, IKKβ and NIK mutants on Tax-mediated activation
of the CD69 promoter. Jurkat cells were transfected with pAIM 1.4-luc (5 μg) together with Tax (1 μg) and the indicated dominant-negative mutants or empty vector (5 μg). The
activities are expressed relative to that of cells transfected with pAIM 1.4-luc and empty vectors, which was deﬁned as 1. Data are mean ± SD. LUC, luciferase.
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suggesting that signaling components involved in the activation of
NF-κB are necessary for Tax transactivation of the CD69 promoter.3.5. Tax-induced CD69 promoter activity is inﬂuenced by other cis-acting
elements
The sequence spanning the−78 to +16 region contains a putative
binding site for early growth response (Egr) at −69 to −61 bp, a com-
posite binding site for Sp1 and Egr at−56 to−47 bp, a CREB binding
site at−46 to−39 bp, and two putative AP-1 binding sites at−16 to
−10 bp and +1 to +7 bp (Fig. 5A). To study the relative contribution
of these cis-acting elements to the inducible CD69 promoter activity,
site-directed mutagenesis of these motifs was performed [35]. Single
mutation of the AP-1 and Egr binding sites did not result in marked
modiﬁcation of the upregulation of CD69 promoter. In contrast, single
mutation of the CREB binding site showed a signiﬁcant reduction of
the inducible activities compared with the wild type plasmid pAIM
78-luc. Except for the Egr69 + AP-1 mutant, different combinations of
doublemutants produced signiﬁcant loss of inducibilitywith the largest
effect in themutants Egr56 + CREB. The transfection of triple or succes-
sive mutants resulted in severe defect with complete abolition of the
Tax-induced effect, for example the Egr69 + Egr56 + CREB mutant
that displayed the same effect that the complete mutation of all the
sites. In contrast, these mutations did not signiﬁcantly affect the basalpromoter activity of CD69. These results indicate that Egr and CREB
binding sites also regulate Tax-induced upregulation of CD69.
We also tested the potential role of CREB inmodulating Tax-induced
CD69 promoter activity. For this purpose, the dominant-negative CREB
mutants KCREB and CREB133were transfected into Jurkat cellswith the
CD69 promoter construct pAIM 1.4-luc or pAIM 78-luc aswell as an ex-
pression vector for Tax. KCREB contains mutations in its DNA binding
domain [48]. CREB133 contains a Ser-to-Ala mutation corresponding
to amino acid 133, and this mutation blocks CREB phosphorylation,
thus preventing transcription [48]. Compared with transfections of an
empty vector, KCREB- and CREB133-expressing Jurkat cells showed lit-
tle Tax-induced upregulation of CD69 (Fig. 5B), suggesting that CREB is
also required for Tax-induced activation of CD69 promoter.
3.6. HTLV-1 and Tax elicit NF-κB subunit binding to CD69 NF-κB elements
We also determined whether HTLV-1 infection elicited NF-κB
binding to the NF-κB elements (κB1 and κB2) in the CD69 promoter
in vitro. EMSA was performed with double-stranded oligonucleotides
representing the NF-κB elements. Protein complexes bound to the
κB1 and κB2 sites were detected with nuclear extracts derived from
all of the HTLV-1-infected T-cell lines examined, but not the control
uninfected Jurkat cells (Fig. 6A). In HTLV-1-infected T-cell lines, espe-
cially, HTLV-1-transformed T-cell lines exhibited high level of protein
complexes. The speciﬁcity of DNA-protein complex formation was
determined by competition studies with unlabeled competitors. As
Fig. 5. Tax induction of CD69 promoter activity is controlled by various cis-acting elements. (A) Functional effects of the mutation of AP-1, Egr and CREB binding sites in the CD69
promoter. Jurkat cells were transiently transfected with the pAIM 78-luc, pAIM 78(AP-1m)-luc plasmids or with the AP-1, Egr69, Egr56 and CREB single, double and multiple mu-
tated versions (5 μg) together with either empty vector or pβMT-2 Tax (2 μg). The mutated plasmids are indicated on the left side of the ﬁgure. The activities are expressed relative
to that of cells transfected with pAIM 78-luc and an empty vector, which was deﬁned as 1. (B) Functional effects of CREB-dominant-negative mutants on Tax-mediated activation of
CD69 promoter. Jurkat cells were transfected with either pAIM 1.4-luc or pAIM 78-luc (5 μg) together with Tax (2 μg) and KCREB, CREB133 or empty vector (5 μg). The activities are
expressed relative to that of cells transfected with pAIM 1.4-luc or pAIM 78-luc and empty vectors, which were deﬁned as 1. Data are mean ± SD. LUC, luciferase.
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otide or consensus NF-κB site from the IL-2Rα promoter effectively
competed with the labeled probes and eliminated the binding of nucle-
ar extracts from HUT-102 cells (Fig. 6B, lanes 1–4). An unlabeled IL-8
AP-1 element did not compete with labeled probes (Fig. 6B, lanes 1
and 5). The exact composition of the transcription factor DNA-protein
complexes in HTLV-1-infected T cells was ascertained by supershift
analysis. Supershift reactions performed using HUT-102 nuclear ex-
tracts identiﬁed p50, p65, c-Rel and RelB as the predominant compo-
nents of the NF-κB complexes (Fig. 6B, lanes 6–8 and 10). We also
found that Tax alone elicited binding to the CD69 κB1 and κB2 probes
with nuclear extracts derived from JPX-9 cells (Fig. 6C). Induction of
Tax expression resulted in the formation of complexes with the probes
within 24 h, and these complexes were eliminated by competitionwith
excess unlabeled CD69 κB1 or κB2 oligonucleotide or the IL-2Rα NF-κB
site, but not by the AP-1 element (Fig. 6D, lanes 2–6). Supershift analysis
performedwith JPX-9 cells indicated that p50, p65, c-Rel and RelBwere
the major NF-κB factors induced after 72 h treatment with CdCl2
(Fig. 6D, lanes 7–9 and 11). These results suggest that HTLV-1 infection
and Tax expression result in the binding of the NF-κB complex to the
NF-κB elements of the CD69 promoter.
3.7. CD69 expression is silenced by deacetylation in MT-2
Finally, we analyzed the reason for the lack of CD69mRNA and pro-
tein in Tax-expressing MT-2 cells. We hypothesized that the CD69 gene
may be silenced by an epigenetic mechanism in this cell line. Histone
deacetylation and methylation are two common mechanisms of epige-
netic silencing of genes [49]. To determine if CD69 was silenced bymethylation, MT-2 cells were treated with the demethylating agent
5-Aza. Such treatment did not restore CD69 expression (Fig. 7A and
B). However, treatment of MT-2 cells with SAHA, a histone deacetylase
inhibitor, restored CD69 expression. Furthermore, treatment of cells
with SAHA together with 5-Aza resulted in restoration of CD69 to a
level similar to that seen with treatment with SAHA alone. The expres-
sion of Tax was similar in all samples (Fig. 7A and B). It was reported
previously that the IL-13 promoter in MT-2 cells is silenced by DNA
methylation [50]. We exploited this phenomenon and readily detected
IL-13 mRNA in 5-Aza-treated MT-2 cells (Fig. 7A and B). In contrast,
treatment ofMT-2 cellswith SAHA alonewas unable to induce IL-13 ex-
pression (Fig. 7A and B). As expected, cell surface CD69 was detected in
MT-2 cells treated with SAHA but not in those treated with 5-Aza
(Fig. 7C). These results suggest that CD69 is silenced by deacetylation,
but not methylation, in Tax-expressing MT-2 cells.
4. Discussion
The major ﬁndings of the present study were: (1) upregulation of
CD69 mRNA in Tax-expressing HTLV-1-transformed T-cell lines and
PBMCs from patients with ATL; (2) presence of cell surface CD69 in
HTLV-1-transformed T-cell lines and fresh peripheral blood ATL cells
only from a minority of patients, (3) among HTLV-1-transformed
T-cell lines, MT-2 cells do not express CD69 due to epigenetic silencing
by histone deacetylation, (4) expression of CD69 protein in ATL cells
present in lymph nodes and skin lesions; (5) HTLV-1 Tax protein in-
duces the expression of CD69 in HTLV-1-negative T cells; (6) Tax-
induced activation of the CD69 promoter is mediated through the
NF-κB and CREB signaling pathways; and (7) Tax-induced expression
Fig. 6. In vitro binding of NF-κB to the NF-κB sites in the CD69 promoter. (A) HTLV-1 infection is associated with binding of NF-κB to the NF-κB sites in CD69 promoter. Nuclear extracts
(5 μg) from control uninfected andHTLV-1-infected T-cell lineswere incubatedwith the labeled double-strandedDNAprobes representing the CD69 κB1 and κB2 sites in EMSA reactions.
(C) Tax-inducedNF-κB binding activity. Nuclear extracts from JPX-9 cells treatedwith CdCl2 (20 μM) for the indicated time periodswere incubatedwith the labeled double-strandedDNA
probes representing the CD69 κB1 and κB2 sites. Nuclear extracts from HUT-102 cells (B) and JPX-9 cells treated with CdCl2 (20 μM) for 72 h (D) were subjected to competition analysis
with an excess of unlabeled double-stranded oligonucleotides representing the CD69 κB1 and κB2 sites (lanes 2 and 3 in B and lanes 3 and 4 in D), a consensus NF-κB site from the IL-2Rα
promoter (lane 4 in B and lane 5 in D) or an AP-1 site from the IL-8 promoter (lane 5 in B and lane 6 in C). The indicated unlabeled oligonucleotides were incubatedwith nuclear extracts
for 15 min prior to binding reactions. Nuclear extracts were also subjected to supershift assayswith either no antibody (lane 1 in B and lane 2 in D) or the indicated antibodies (Ab) (lanes
6–10 in B and lanes 7–11 in D). The antibodieswere incubatedwith nuclear extracts for 45 min prior to binding reactions. Arrows: speciﬁc complexes, arrowhead: the DNA binding com-
plex supershifted by the antibody.
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the interplay of transcription factors of the NF-κB, CREB and Egr
families.
The results showed that Tax enhanced cell surface expression of CD69
with JPX-9 cells, a Jurkat cell line that expresses Tax in an inducible man-
ner, as reported previously by Chlichlia et al. [51], who constructed fusion
proteins containing Tax and the hormone binding domain of the estrogen
receptor. However, little or no information is available regarding the un-
derlying mechanism of regulation of CD69 expression by Tax. Therefore,
we focused mainly on the identiﬁcation of the cis-acting sequences and
nuclear factors involved in Tax-inducible expression of the CD69-
encoding gene. The NF-κB family of transcription factors plays an impor-
tant role in the regulation of CD69 expression [34]. The κB2, but not κB1,
motif plays a key role in tumor necrosis factor-α-induced promoter
activity in K562 erythroleukemic cells. However, deletion of the sequence
that contains the κB2 motif (nucleotides −255 to −170) reduced Tax-
mediated transactivation, but did not completely abolish the response
to Tax. Further deletion of upstream sequences up to position −78
resulted in decreased promoter strength of the response to Tax. These
results strongly indicate that additional Tax-responsive elements are
present in the sequence that contains the κB1 motif (nucleotides−170
to −78). Therefore, to deﬁne unambiguously the contribution of κB2
and κB1motifs to the response to Tax,we deleted thesemotifs in the con-
text of the intact promoter. When the κB2 or κB1 was deleted, signiﬁcant
suppression of CD69 promoter activation was observed compared with
the control. The combination of double deletions reduced Tax-mediatedtransactivation compared with single deletion of the κB2 or κB1, but
did not completely abolish it. Our results also demonstrated that the
two NF-κB motifs of the CD69 promoter bind Tax-inducible NF-κB-
related complexes. These results suggest that both κB2 and κB1 mo-
tifs play a key role in Tax-induced promoter activity, although other
cis-acting elements in the promoter region spanning positions−78
to +16 also seemed to play a role in this process. Mutation analysis
of the CD69 promoter identiﬁed three other cis-acting elements:
two Egr (−69 and −56) and one CREB (−46) binding sites, which
control in a coordinated manner the Tax-mediated upregulation of
CD69 expression. Interestingly, although single mutation or deletion
of the different binding sites moderately altered Tax-induced activa-
tion, the combined mutation or deletion of various cis-acting ele-
ments was necessary to abolish the effect of Tax. In summary, the
inducible expression of CD69 gene appears to be tightly regulated
by transcription factors of the NF-κB, Egr and CREB families.
Tax expression correlates with the upregulation of CD69 mRNA and
protein in human T-cell lines. It is a paradox that HTLV-1 Tax contrib-
utes to the pathogenesis of ATL while its protein is undetectable in pe-
ripheral blood ATL cells. Indeed, ATL-derived T-cell lines that lack Tax
protein expression, such as MT-1, TL-OmI and ED-40515(−), also lack
CD69. We also examined CD69 in patients with ATL. Although PBMCs
from patients with ATL expressed CD69mRNA, CD69 on the cell surface
was upregulated only in aminority of patients. However, immunohisto-
chemical staining identiﬁed ATL cells positive for CD69 on the cell sur-
face in all lymph nodes and skin tissue samples examined. We are
Fig. 7. CD69 is silenced by deacetylation, but notmethylation. (A) RT-PCR analysis of CD69, IL-13, Tax and GAPDHmRNA expression inMT-2 cells treatedwith orwithout 5-Aza (2.5 μM),
SAHA (2.5 μM), 5-Aza (2.5 μM) plus SAHA (2.5 μM) for 24–72 h. (B) RT-PCR analysis of CD69, IL-13, Tax and GAPDH mRNA expression in MT-2 cells treated for 24 h with either 5-Aza
(2.5, 5 and 10 μM) alone, SAHA (2.5 μM) alone, or in combination with SAHA (2.5 μM), together with 5-Aza (2.5, 5 and 10 μM). (C) Cell surface expression of CD69 protein inMT-2 cells
treated with or without 5-Aza (2.5, 5 and 10 μM), SAHA (2.5 μM), and the combination of 5-Aza (2.5, 5 and 10 μM) plus SAHA (2.5 μM) for 24 h. Cells were stained with PE-conjugated
anti-CD69 antibody (black/solid). Control cells were stained with control antibody of the same isotype as the anti-CD69 antibody (lined/open).
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that ATL cells from a patient with ATL cultured ex vivo exhibit induction
of CD69 mRNA and protein in parallel with Tax mRNA. Interestingly,
one study described increased number of CD69-expressing T cells
after 2-day culture, in patients with HTLV-1-associated myelopathy/
tropical spastic paraparesis and carriers but not in controls [52]. These
data are in agreement with our results. It has been also reported that
T cells cultured ex vivo from ATL patients exhibit a potent block in the
induction of CD40 ligand (CD40L), but not CD69 in response tomitogen
stimulation overnight [53]. However, culturing ATL PBMCs leads to a
progressive increase in Tax expression, and restores the capacity to
upregulate CD40L for 72 h. Thus, Tax expression, or possibly another
factor induced by culturing the cells, may be essential to induce CD69
and CD40L.
Apparently, there is no doubt that Tax can transactivate the CD69
promoter. However, the intensity of the RT-PCR product of CD69 did
not correlate with the level of expression of Tax in primary ATL cells
in vivo. Constitutive high NF-κB activity has typically demonstrated
in ATL cells in which Tax expression is repressed in vivo [54]. Thus,
Tax is not the only mechanism for expression of CD69 in ATL cells.
Rather, the NF-κB activation might be necessary for expression of
CD69.
It is possible that HTLV-1may require CD69 in a transient manner for
a function perhaps related to viral life cycle and therefore may not need
constitutive expression of CD69. The expression of activated cell anti-
gens, such as CD25 (IL-2Rα) and CD28, is high while that of CD7 is low
in peripheral blood ATL cells from patients with both acute and chronic
ATL. On the other hand, high expression of HLA-DR antigen is reported
in peripheral blood ATL cells from patients with chronic ATL, but not in
those from patients with acute ATL. Interestingly, CD7 and HLA-DRantigens are detected on the majority of lymph node ATL cells [55]. Fur-
thermore, HTLV-1-infected T-cell lines express CD7 andHLA-DR [55–57].
Paradoxically, we found that CD69 antigen on ATL cells in lymph nodes
and skin tissues, and on Tax-expressing HTLV-1-transformed T-cell
lines, but not on themajority of peripheral bloodATL cells. Theseﬁndings
can be linked with previous reports that lymph node ATL cells are more
activated than peripheral blood ATL cells [55,58]. CD69 forms a complex
with sphingosine-1-phosphate on T lymphocytes, which promotes the
downregulation of sphingosine-1-phosphate surface expression, induc-
ing lymphocyte retention in the lymph nodes [59]. It is possible that
CD69-positive cells in lymph nodes were transformed by HTLV-1 infec-
tion and the cells devoid of CD69, migrated to peripheral blood. Further
studies are needed to examine the functional role of CD69 on lymph
node ATL cells.
In conclusion, CD69 is a Tax-regulated gene, and the induction of
CD69 gene expression by Tax is regulated by multiple cis-acting ele-
ments and by the interplay of transcription factors of the NF-κB, Egr
and CREB families. The broad mRNA expression contrasts with the re-
stricted protein expression of CD69 in peripheral blood ATL cells,
suggesting that lack of Tax expression and post-transcriptional regula-
tory mechanisms may control CD69 protein expression. Further analy-
sis of the role of cellular cofactors and effects of Tax on chromatin
structure and histone deacetylation at the CD69 promoter should be
informative.
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